Repligen Corporation (RGEN)
OvervaluedFundamental
55
Price
$192.23
Market Cap
$10.85B
Part 1 · What the company is worth
Overview
Repligen Corporation, a life sciences company, develops and commercializes bioprocessing technologies and systems in North America, Europe, the Asia Pacific, and internationally. The company's products include hollow fiber consumables, KRM chromatography system, resins for new modalities, PATsmart MAVERICK and PATsmart MAVEN for real-time monitoring and control of critical bioprocess parameters, PATsmart REBEL, an at-line cell culture media analyzer; and PATsmart ZipChip, a high-resolution sample separations device, PATsmart SoloVPE slope spectroscopy system, and SoloVPE PLUS System. It offers Protien A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company also provides chromatography products, including OPUS pre-packed chromatography columns, which are used in the purification and quality control of biological drugs, as well as ELISA test kits. In addition, it offers filtration products, such as XCell ATF Cell Retention Systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration, buffer exchange, and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; and ProConnex TFDF flow paths. Further, it provides process analytics products, such as slope spectroscopy systems. The company offers its products under the OPUS, XCell, XCell ATF, TFDF, KrosFlo, SIUS, ProConnex, Spectra/Por, NGL-Impact, SoloVPE, FlowVPE, RPM, XO, Metenova MixOne, and AVIPure and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has a collaboration agreement with Navigo Proteins GmbH to develop multiple affinity ligands. The company was incorporated in 1981 and is headquartered in Waltham, Massachusetts.
No editorial profile for this company yet
Direct competitors
Who this company fights with for the same customers
No editorial profile for this company yet
No competitor list for this company yet.
Balance Sheet & Liquidity
Revenue
$785M
Trailing 12 months (through 6/30/2026)
Net Income
$42M
Trailing 12 months (through 6/30/2026)
Free Cash Flow
$94M
Total Equity
$2.11B
Total Liabilities
$844M
Current Ratio
9.05
Interest Coverage
2.92
Debt/EBITDA
5.16
Earnings Per Share
Revenue & Net Income
Free Cash Flow
Income Breakdown
Historical statement
Margins over time
Debt over time
How heavy the debt is
Growth grid
Growth — Revenue
Fair Value Estimation
Fair Value
$133.58
Current Price
$192.23
Margin of Safety
-43.9%
Fair Value Range
$86.83 - $180.34
Spread across the valuation methods used, not a statistically calibrated confidence interval.
Estimation Methods
Valuation Metrics
P/E Ratio
259.77
ROE
2.3%
P/B Ratio
5.14
P/FCF
96.89
Gross Margin
53.5%
ROIC
1.8%
Profitability Radar
Value Creation (Economic Moat)
ROIC
1.8%
WACC
10.2%
ROIC − WACC
-8.4 pp
ROIC is below the cost of capital — the company is destroying value for every dollar invested.
Fundamental Analysis Criteria
Passed (17)
- EPS shows upward trend
- Price CAGR 19.60%
- Gross Margin 53.5%
- Debt/Equity ratio
- Operating Margin 8.2%
- Positive Free Cash Flow
- CapEx intensity
- Current Ratio
- Interest Coverage
- Debt/EBITDA
- Return on Tangible Assets
- Revenue Growth 5Y 15.1%
- Analyst Consensus 86% Buy
- Earnings Surprise avg 14.2%
- Earnings Quality (OCF/NI) 3.25
- Net Margin Trend 5.3% vs -2.1%
- Piotroski F-Score 7/9
Failed (8)
- ROIC 1.8%
- P/FCF 96.89
- P/B Ratio 5.14
- Low reliance on intangibles
- Price below Graham Number
- DCF valuation (Overvalued)
- ROE 2.0%
- Share Dilution 2.5%
Unavailable (2)
- Dividend Payout NaN%
- PEG Ratio (need PE > 0 and growth > 0)
Piotroski F-Score
Strong financial health
Earnings Quality
High quality: earnings backed by cash
Share Dilution
Issuing new shares, diluting ownership
Institutional Holdings
Governance
Executive Team
| Name | Title | Age |
|---|---|---|
| Mr. Olivier Loeillot | President, CEO & Director | 55 |
| Mr. Jason K. Garland | CFO & Chief Compliance Officer | 51 |
| Mr. James R. Bylund | Chief Operating Officer | 62 |
| Mr. Anthony J. Hunt | Advisor | 61 |
| Mr. Ralf Kuriyel | Senior Vice President of Research & Development | 67 |
| Mr. Brian Douglass | Senior VP & Chief Product Officer | 50 |
| Ms. Violetta Hughes | Chief Accounting Officer | 52 |
| Ms. Heather Ems | Chief Information Officer | - |
| Mr. Jacob K. Johnson C.F.A. | Vice President of Investor Relations | - |
| Mr. George A Scott Jr., J.D., M.B.A. | Senior VP & General Counsel | - |
Audit Risk
10
Board Risk
4
Compensation Risk
5
Shareholder Rights Risk
1
Part 2 · The price and when to enter
This part won't tell you whether the company is worth owning: it helps you choose when to buy it, once the fundamentals have convinced you. Inside: technical analysis, potential, historical drawdowns, gamma exposure.
Documents
- View document
Annual Report (10-K)
A yearly overview of the business, its financial results, and the risks it faces.
Filed on 2026-02-26
- View document
Quarterly Report (10-Q)
A snapshot of financial performance for the most recent three-month period.
Filed on 2026-07-29
- View document
Current Report (8-K)
An announcement of a major event, such as a leadership change or big news.
Filed on 2026-09-15
via SEC EDGAR
Income History
via SEC EDGAR
Latest News
Recent headlines for RGEN, sourced from Markets Gazette.
- 2/24/2026NEUTRALRepligen (RGEN) Q4 2025 Earnings Call Transcript
Markets Gazette reports that the transcript for Repligen Corporation's (RGEN) Q4 2025 earnings call is now available. While specific details are not disclosed here, investors and analysts eagerly await an in-depth review of this document. Earnings call transcripts are crucial for understanding past financial performance, future projections, and corporate strategies. Market participants will be looking for insights into revenues, margins, product pipeline, and management's commentary regarding the life sciences sector outlook. The availability of such information is a standard event in the financial calendar, but its market impact will entirely depend on the data and statements contained within, which will guide future investment decisions.
via Markets Gazette